Goldman Sachs Reportedly Agrees To Pay U.S. $2.8 Bln To Settle 1MDB Probes

Goldman Sachs Group Inc. (GS) has reached an agreement with the U.S. Department of Justice to pay about $2.8 billion for the bank's role in Malaysia's 1MDB scandal, the Wall Street Journal reported citing people familiar with the matter.

The bank's subsidiary in Asia tied to the misconduct is expected to plead guilty this week, while the parent company will accept deferred prosecution agreement, the Journal reported.

The settlement with the Justice Department, expected as soon as this week, would settle an investigation into Goldman's work for a corrupt Malaysian government fund known as 1MDB.

The settlement follows an agreement in July to settle a related probe with Malaysia, in which the bank agreed to pay $2.5 billion.

Malaysia had agreed to withdraw the pending criminal charges and agreed that no further charges would be brought against Goldman Sachs, its subsidiaries, or any of their directors, officers and employees (excluding former employees Tim Leissner and Roger Ng) related to 1MDB.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Hedge-fund billionaire William Ackman's Pershing Square Tontine Holdings Ltd. (PSTH) agreed to acquire 10% of Universal Music Group from French media conglomerate Vivendi (VIV.L, VIVEF.PK) for about $4 billion, the companies said in a statement on Sunday. The 737 MAX 10, Boeing Co.'s largest 737 Max model, is taking its maiden flight today, reports said citing people familiar with the matter. The flight after months of testing and certification will be around 10 a.m. local time from the Seattle area. The schedule could change depending on weather or other factors. Meanwhile, the jetliner is expected to enter commercial service in 2023. Medical devices supplier Smiths Medical, affiliated to Smiths Group plc, is recalling certain Jelco Hypodermic Needle-Pro Fixed Needle insulin syringes with skewed graduation markings, the U.S. Food and Drug Administration said. The recall was initiated after the company became aware of specific models and lots of Jelco insulin syringes that may exhibit skewed odd number line graduation markings.
Follow RTT